A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
Incyte (INCY) stock and Xencor (XNCR) stock are in focus as jointly developed antibody drug tafasitamab succeeds in a ...
BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...
How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback